131I治疗Graves病合并白细胞减少的临床评价

    Iodine-131 for the treatment of Graves disease complicated with leukopenia

    • 摘要: 目的:观察131I对Graves病(GD)合并白细胞减少患者治疗的疗效影响及安全性。方法:对131I 治疗66 例GD合并白细胞减少患者前后的游离三碘甲状腺原氨酸(FT3)、游离甲状腺素(FT4)、白细胞水平及治愈率等临床资料进行回顾性分析。结果:GD合并白细胞减少患者经131I治疗3、6和12个月时的FT3 和FT4水平与治疗前差异均有统计学意义(P<0.01);而治疗后1个月时的FT3 、FT4及白细胞水平与治疗前差异均无统计学意义(P>0.05),治疗后6个月,治愈43例,白细胞恢复正常60例,好转6例。结论:GD合并白细胞减少患者经131I治疗后,随着GD的治愈,绝大多数GD合并白细胞减少患者白细胞恢复正常或明显改善,是一种安全有效的治疗方法。

       

      Abstract: Objective: To investigate the clinical effect and safety of iodine-131(131I) in the treatment of Graves disease(GD) complicated with leukopenia.Methods: Sixty-six cases of GD complicated with leukopenia were treated by 131I,and the levels of free triiodthyronine(FT3),free thyroxine(FT4),leukocyte and the curative effects were analyzed retrospectively.Results: The levels of FT3 and FT4 at 3,6 and 12 months after 131I therapy reduced markedly(P<0.01),but there was no significant difference among FT3,FT4 or leukocyte at 1 month after 131I therapy(P>0.05).After 6 months' treatment,the GD in 43 cases were cured,the leukocyte in 60 cases returned normal and 6 cases improved.Conclusions: After the therapy of 131I,most of GD patients complicated with leukopenia are cured or turn better.131I therapy is effective and safe for the treatment of GD complicated with leukopenia.

       

    /

    返回文章
    返回